EARGO, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On January 4, 2023, Eargo, Inc. (“Eargo” or the “Company”) issued a press
release announcing the launch of its new, seventh generation product, Eargo 7,
at CES 2023. Eargo also announced that it had received U.S. Food and Drug
Administration
(“FDA”) 510(k) clearance for Eargo 5 and Eargo 6 as self-fitting
hearing aids. A copy of the press release is furnished as Exhibit 99.1 hereto
and is incorporated herein by reference.

The information in this Item 7.01, including the exhibit hereto, shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section 11
and 12(a)(2) of the Securities Act of 1933, as amended. The information
contained herein and in the accompanying exhibit shall not be incorporated by
reference into any filing with the U.S. Securities and Exchange Commission made
by the Company, whether made before or after the date hereof, regardless of any
general incorporation language in such filing.


Item 8.01 Other Events.


On December 22, 2022, Eargo received FDA 510(k) clearance for Eargo 5 and 6 as
self-fitting hearing aids. Eargo is launching Eargo 7 as its third
over-the-counter, self-fitting device. The Eargo self-fitting hearing aids are
intended to amplify and transmit sound to the ear and compensate for perceived
mild to moderate hearing impairment in individuals 18 years of age or older.
They are adjusted by the user to meet the user’s hearing needs. No
pre-programming or hearing test is necessary. The products are intended to be
used without the assistance of a hearing care professional. As previously
disclosed, the Company plans to market its devices as over-the-counter (“OTC”)
hearing aids and intends to comply with all applicable OTC regulatory
requirements as of the compliance date for currently marketed devices on April
14, 2023
, or sooner. In addition, the Company may seek to market certain devices
as prescription hearing aids, which would require compliance with separate
physical and electronic labeling requirements under the FDA’s OTC final rule.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended. All statements other than statements of
historical fact contained in this Current Report are forward-looking statements,
including statements regarding the intended use of Eargo products and the
Company’s marketing plans and compliance with applicable OTC regulatory
requirements. Forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties and assumptions that could
cause actual results and events to differ materially from those anticipated,
including, but not limited to, risks, uncertainties and assumptions related to:
the extent to which the Company may be able to validate processes to support the
submission of claims for reimbursement from the FEHB program or other insurance
programs in the future, if at all, and the Company’s ability to maintain or
increase insurance coverage of Eargo hearing aids; the timing or results of
ongoing claims audits and medical records reviews by third-party payors; the
impact of third-party payor audits and the regulatory landscape for hearing aid
devices on the Company’s business and results of operations; the Company’s
expectations concerning additional orders by existing customers; the Company’s
expectations regarding the potential market size and size of the potential
consumer populations for its products and any future products, including
insurance coverage of Eargo hearing aids; the Company’s ability to release new
hearing aids and the anticipated features of any such hearing aids; developments
and projections relating to the Company’s competitors and its industry,
including competing products; the Company’s ability to maintain its competitive
technological advantages against new entrants in its industry; the pricing of
the Company’s hearing aids; the Company’s expectations regarding the ability to
make certain claims related to the performance of its hearing aids relative to
competitive products; the Company’s expectations with regard to changes in the
regulatory landscape for hearing aid devices, including the implementation of
the OTC hearing aid regulatory framework and the Company’s assessment, ability
and timing for compliance with the new requirements; and the Company’s estimates
regarding the COVID-19 pandemic, including, but not limited to, its duration and
its impact on the Company’s business and results of operations. These and other
risks are described in greater detail under the section titled “Risk Factors”
contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form
10-Q and other filings with the U.S. Securities and Exchange Commission. Any
forward-looking statements in this Current Report are made pursuant to the
Private Securities Litigation Reform Act of 1995, as amended, are based on
current expectations, forecasts and assumptions, and speak only as of the date
of this Current Report. Except as required by law, the Company undertakes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise.

——————————————————————————–

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.


Exhibit
  No.      Description
  99.1     Press Release dated January 4, 2023.
104        Cover Page Interactive Data File (embedded within the inline XBRL document).


——————————————————————————–

© Edgar Online, source Glimpses

Leave a Comment